📊 SABSW Key Takeaways
Is SAB Biotherapeutics, Inc. (SABSW) a Good Investment?
SAB Biotherapeutics is a pre-revenue company with zero revenue and severe cash burn. Despite positive reported net income (driven by one-time gains), the company is losing $49M operationally and burning $45.7M in free cash flow annually with only $10.5M cash remaining. At current burn rates, the company faces critical funding pressure within months.
SAB Biotherapeutics, Inc. Key Strengths (SABSW)
- Zero long-term debt (Debt/Equity: 0.00x) eliminates leverage risk
- Strong current ratio of 9.46x indicates near-term liquidity from current assets
- Asset base of $172.8M provides some operational runway with $151.5M equity
SABSW Stock Risks: SAB Biotherapeutics, Inc. Investment Risks
- Zero revenue with -100% YoY decline indicates complete revenue loss or pre-revenue stage with failed commercialization
- Operating cash burn of -$44.8M against only $10.5M cash creates imminent solvency risk without external funding
- Positive net income of $13.3M contradicts -$49M operating loss, indicating reliance on one-time gains (non-operational) not sustainable profits
- Free cash flow negative at -$45.7M; company will deplete cash within 2-3 months at current burn rate
- EPS remains deeply negative at -0.79 despite reported positive net income, indicating significant dilution pressure
Key Metrics to Watch
- Cash runway and timeline to next funding event (critical survival metric)
- Quarterly cash burn trend and operating loss trajectory
- Revenue recognition or clinical trial progress (only path to operational viability)
SAB Biotherapeutics, Inc. (SABSW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.46x current ratio provides a solid financial cushion.
SABSW Profit Margin, ROE & Profitability Analysis
SABSW vs Healthcare Sector: How SAB Biotherapeutics, Inc. Compares
How SAB Biotherapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is SAB Biotherapeutics, Inc. Stock Overvalued? SABSW Valuation Analysis 2026
Based on fundamental analysis, SAB Biotherapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
SAB Biotherapeutics, Inc. Balance Sheet: SABSW Debt, Cash & Liquidity
SABSW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: SAB Biotherapeutics, Inc.'s revenue has declined by 98% over the 5-year period, indicating business contraction. The most recent EPS of $-3.68 indicates the company is currently unprofitable.
SABSW Revenue Growth, EPS Growth & YoY Performance
SABSW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.2M | -$5.0M | $-0.21 |
| Q2 2025 | $263.1K | -$5.0M | $-0.79 |
| Q1 2025 | $944.6K | -$5.0M | $-0.54 |
| Q3 2024 | $1.2M | -$5.0M | $-0.97 |
| Q2 2024 | $85.5K | -$5.0M | $-0.79 |
| Q1 2024 | $581.1K | -$5.0M | $-0.54 |
| Q3 2023 | $1.3M | $985.9K | $-0.10 |
| Q2 2023 | $85.5K | $985.9K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
SAB Biotherapeutics, Inc. Dividends, Buybacks & Capital Allocation
SABSW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for SAB Biotherapeutics, Inc. (CIK: 0001833214)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SABSW
What is the AI rating for SABSW?
SAB Biotherapeutics, Inc. (SABSW) has an AI grade of D with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SABSW's key strengths?
Claude: Zero long-term debt (Debt/Equity: 0.00x) eliminates leverage risk. Strong current ratio of 9.46x indicates near-term liquidity from current assets.
What are the risks of investing in SABSW?
Claude: Zero revenue with -100% YoY decline indicates complete revenue loss or pre-revenue stage with failed commercialization. Operating cash burn of -$44.8M against only $10.5M cash creates imminent solvency risk without external funding.
What is SABSW's revenue and growth?
SAB Biotherapeutics, Inc. reported revenue of $0.0.
Does SABSW pay dividends?
SAB Biotherapeutics, Inc. does not currently pay dividends.
Where can I find SABSW SEC filings?
Official SEC filings for SAB Biotherapeutics, Inc. (CIK: 0001833214) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SABSW's EPS?
SAB Biotherapeutics, Inc. has a diluted EPS of $-0.79.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SABSW's fundamental grade?
Based on our AI fundamental analysis in June 2026, SAB Biotherapeutics, Inc. has a D grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SABSW stock overvalued or undervalued?
Valuation metrics for SABSW: ROE of 8.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SABSW's AI grade for 2026?
Our dual AI analysis gives SAB Biotherapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SABSW's free cash flow?
SAB Biotherapeutics, Inc.'s operating cash flow is $-44.8M, with capital expenditures of $933.2K.
How does SABSW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE 8.8% (avg: 15%), current ratio 9.46 (avg: 2).